Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AEROLATE SR vs DECASPRAY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Decaspray contains dexamethasone, a potent synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. This results in anti-inflammatory and immunosuppressive effects through inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, suppression of cytokine production, and decreased capillary permeability.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Inflammatory dermatoses (e.g., eczema, dermatitis),Allergic skin reactions,Psoriasis,Lichen planus,Discoid lupus erythematosus
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
2-4 metered sprays (400-800 mcg) intranasally twice daily. Maximum 8 sprays (1600 mcg) per day.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
The terminal elimination half-life is approximately 3-4 hours in adults. This short half-life is consistent with its classification as a long-acting glucocorticoid due to high potency and prolonged tissue effects, not extended plasma presence.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Dexamethasone is metabolized primarily in the liver via cytochrome P450 3A4 (CYP3A4) to inactive metabolites.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Decaspray (dexamethasone) is primarily metabolized in the liver, with less than 10% excreted unchanged in urine. Minor biliary excretion occurs, but fecal elimination is negligible. Overall, renal excretion accounts for >90% as metabolites, with <10% as parent drug.
55–65% bound to plasma proteins, primarily albumin.
Approximately 77% bound to serum proteins, primarily albumin and corticosteroid-binding globulin (CBG).
0.4–0.6 L/kg, indicating distribution into total body water.
Volume of distribution is approximately 0.8 L/kg (range 0.5-1.0 L/kg). This indicates moderate distribution into tissues, with higher penetration into CNS compared to other glucocorticoids.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
Oral bioavailability is approximately 80-90%. Intramuscular bioavailability is nearly 100% due to complete absorption. Intranasal bioavailability is low (<1%) due to local administration, but systemic absorption can occur with high doses.
No dose adjustment required for renal impairment.
No adjustment required for any degree of renal impairment.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
No adjustment required for Child-Pugh Class A or B. For Child-Pugh Class C, caution advised due to lack of data; monitor for systemic effects.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Children 2-11 years: 1-2 sprays (200-400 mcg) intranasally twice daily. Maximum 4 sprays per day.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
Same as adult dosing. No specific dose reduction required; monitor for adrenal suppression in prolonged use.
No FDA black box warning exists for this drug.
None
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Topical corticosteroids may cause systemic absorption, leading to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. Systemic absorption is increased with use on large surface areas, prolonged use, occlusive dressings, or in pediatric patients. Avoid use on face, groin, or axillae unless directed. Use caution in patients with bacterial, fungal, or viral skin infections; may mask or worsen infection. Discontinue if irritation or sensitization occurs.
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Hypersensitivity to dexamethasone or any component of the formulation; untreated bacterial, fungal, or viral skin infections; tuberculous skin lesions; syphilitic skin infections; vaccinia or varicella; perioral dermatitis; rosacea; acne vulgaris; broken or abraded skin.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
No known food interactions. Avoid excessive intake of potassium-rich foods if prolonged use on large areas to mitigate risk of hypokalemia.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
FDA Category C. First trimester: potential for orofacial clefts, though absolute risk low. Second/third trimester: risk of intrauterine growth restriction, oligohydramnios, and premature closure of ductus arteriosus with prolonged use.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Limited data; small amounts of dexamethasone excreted into breast milk; M/P ratio approximately 0.3-0.5. Theoretical risk of adrenal suppression; avoid high doses or monitor infant for growth and adrenal function.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
No standard dose adjustment; use lowest effective dose. Increased clearance in third trimester may require higher doses to achieve therapeutic effect; monitor clinical response and adjust accordingly.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Decaspray (dexamethasone topical aerosol) is a potent corticosteroid for dermatologic use. Avoid use on infected skin without concurrent anti-infective therapy. Limit application to small areas and use sparingly to minimize systemic absorption. Do not use on face, groin, or axillae due to risk of atrophy. Discontinue if irritation or sensitization occurs.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
Apply a thin film only to affected skin areas as directed.,Do not cover the treated area with bandages unless instructed by your doctor.,Avoid contact with eyes, mouth, or open wounds.,Do not use on diaper rash or under diapers.,Wash hands after application unless treating hands.,Inform your doctor if condition worsens or does not improve after 2 weeks.,Do not use for other conditions without consulting a healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AEROLATE SR vs DECASPRAY, answered by our medical review team.
AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. DECASPRAY is a Intranasal Corticosteroid that works by Decaspray contains dexamethasone, a potent synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene transcription. This results in anti-inflammatory and immunosuppressive effects through inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, suppression of cytokine production, and decreased capillary permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AEROLATE SR and DECASPRAY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. The standard adult dose of DECASPRAY is: 2-4 metered sprays (400-800 mcg) intranasally twice daily. Maximum 8 sprays (1600 mcg) per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AEROLATE SR and DECASPRAY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. DECASPRAY is classified as Category C. FDA Category C. First trimester: potential for orofacial clefts, though absolute risk low. Second/third trimester: risk of intrauterine growth restriction, oligohydramnios, and pre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.